Saudi Arabia targets global biotech leadership by 2040 with a four-pillar strategy. Saudi Arabia targets global biotech leadership by 2040 with a four-pillar strategy.
Xcell Therapeutics is developing completely animal-origin-free, chemically defined stem-cell media, enhancing safety, quality, and reproducibility.
Actithera is pioneering chemistries in radioligand therapy that extend tumor residence time, creating differentiated candidates like its lead fibroblast activation protein-targeted compound.
Bispecific and multispecific antibodies are gaining momentum in oncology research. They accounted for a quarter of the top 20 highest-grossing deals in the year to date, with many transactions focusing on Chinese assets. Bispecific and multispecific antibodies are gaining momentum in oncology research. They accounted for a quarter of the top 20 highest-grossing deals in the year...
This year’s drug development has been characterized by multiple deals signed with companies from China, along with collaborations involving firms specializing in artificial intelligence and antibodies. This year’s drug development has been characterized by multiple deals signed with companies from China, along with collaborations involving firms specializing in artificial...
ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced vaccine and therapeutic applications.
Variational AI is using its Enki platform to explore uncharted regions of the chemical space, accelerating the discovery and development of transformative therapeutics in collaboration with biopharma partners across various high-need therapeutic areas.
The biotech is aiming to develop a first-line consolidation treatment for large B-cell lymphoma that predicts and prevents relapse.
DC-Biotech is using its pioneering, proprietary αNKT technology to leverage the unique immunomodulatory properties of natural killer T-cells and mesenchymal stem cells, accelerating the development of regenerative medical products for diseases with unmet need, particularly those related to immune system dysregulation and inflammation.
Angiocrine Bioscience uses its propriety platform to harness the reparative powers of vascular endothelial cells and develop advanced therapeutics that repair tissue damage and treat chronic conditions.
Candel Therapeutics is driving a paradigm shift in the treatment of solid tumors through the development of novel viral immunotherapies. The company plans to file a Biologics License Application (BLA) for its lead clinical candidate, aglatimagene besadenovec (CAN-2409), for localized prostate cancer in late 2026.
NodThera has developed first-in-class small-molecule inhibitors of the NLRP3 inflammasome, a master switch for inflammation, and is charting a clinical path to patients in multiple indications.
Large biopharma companies are partnering with companies developing drug candidates that harness induced proximity approaches to tackle challenging targets. Large biopharma companies are partnering with companies developing drug candidates that harness induced proximity approaches to tackle challenging targets.
NanoSyrinx is pioneering Nanosyringe technology for targeted intracellular delivery of proteins, a new modality enabling access to undruggable targets and redefining what is possible for biologics.
NEOsphere Biotechnologies is accelerating drug discovery through high-throughput proteomics, enabling efficient screening of molecular glue libraries and systematic identification of clinically relevant degraders.
Although siRNA and ASO assets attracted most upfront cash, a striking trend from the past year has been the scramble for RNA delivery and manufacturing know-how. Although siRNA and ASO assets attracted most upfront cash, a striking trend from the past year has been the scramble for RNA delivery and manufacturing know-how.
Nutcracker Therapeutics is driving down costs, accelerating speed of processing and improving scalability with an end-to-end, GMP-grade production process.
How Nagase Viita’s saccharide innovation can streamline biopharmaceutical production.
A review of the first half of the year’s highest value partnerships, including mergers and acquisitions with the help of DealForma. A review of the first half of the year’s highest value partnerships, including mergers and acquisitions with the help of DealForma.
Novel strategies for developing therapies for neurodegenerative disorders are attracting pharma partners. Novel strategies for developing therapies for neurodegenerative disorders are attracting pharma partners.
With its innovative VECTrans platform, Vect-Horus is enabling targeted drug delivery across the blood–brain barrier, potentially transforming the treatment of neurodegenerative disorders.
Hua Medicine is developing potentially disease-modifying therapeutics for type 2 diabetes, driven by mechanisms in the glucose homeostasis process. Having launched dorzagliatin in China in 2022, the company aims to transform diabetes treatment globally with its next generation glucokinase activator.
Transcenta is employing its unique, cutting-edge discovery technology to develop antibody-based therapies that address unmet medical needs in oncology, immunology and inflammation.